The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug Administration (FDA) as the first prescription drug to help alleviate moderate-to-severe obstructive sleep apnea (OSA) for adults with obesity.
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...
A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.
It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...
Honda and Nissan begin merger talks with a plan for the combination to be completed in 2026, Qualcomm scores a victory in its ...
Weight loss injections have become a popular choice to help people curb their appetite, but can they curb addiction, as well?
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback